Le Lézard
Classified in: Health
Subjects: PDT, WOM

NeuroFlow Launches Perinatal and Postpartum Care Pathways to Fill Critical Gaps in Maternal Mental Health Care


The company has developed a new tailored experience that improves risk detection for a wide range of perinatal mental health conditions and provides proactive support

PHILADELPHIA, May 2, 2024 /PRNewswire-PRWeb/ -- NeuroFlow, a behavioral health technology and analytics company helping to measure and manage population risk, has launched a suite of perinatal and postpartum pathways to support behavioral health throughout and after pregnancy. These programs are a manifestation of NeuroFlow's commitment to improving identification and timely support for behavioral health comorbidities, overcoming systemic barriers to care for populations that lack the resources they need during a vulnerable and momentous time in their lives.

"We're incredibly proud of the work our clinical specialists have done to create an experience that is sensitive, clinically validated, engaging and intuitive," - Julia Kastner, Chief Product Officer of NeuroFlow.

In 2022 the White House declared a maternal health crisis in reaction to rising maternal mortality rates. The vast majority of these deaths are preventable, and over 23% are related to behavioral health conditions. Two years later, parents continue to face this stark reality, as 75% of women with perinatal mental health conditions never receive treatment due to lack of screening or access to care. In particular, low-income women and women of color see large disparities in postpartum behavioral health screenings.

Many organizations are developing solutions to increase access to care for women and families through the pregnancy experience, but most still lack sufficient mechanisms for consistently screening for behavioral health needs at every stage of pregnancy and tailoring resources to what an individual needs. NeuroFlow is tackling the crisis head-on by implementing upstream strategies to identify maternal behavioral health needs through regular screenings and proactive support. This includes prompt outreach for parents experiencing suicidal ideation or thoughts of self-harm. The launch of these much-needed pathways strategically aligns with the goals of Mental Health Awareness Month, a time to increase conversations and to spotlight these pressing issues.

"These new maternal health pathways are a natural extension of NeuroFlow's core functionality ? identifying, supporting, and guiding at-risk populations to the appropriate level of care," said NeuroFlow Chief Product Officer Julia Kastner. "Leveraging real-time population data, we can identify mothers who are at risk, customize the experience to their needs and their stage of pregnancy, and align it with the care they receive from their providers. We're incredibly proud of the work our clinical specialists have done to create an experience that is sensitive, clinically validated, engaging and intuitive."

NeuroFlow's new maternal mental health offering uses enhanced logic to send timely clinically-validated assessments throughout the pregnancy period to identify behavioral health conditions and direct the parent to the right level of care. The personalized experience also includes educational content and milestone planning for each trimester and during the postpartum period, including resources in the event of a lost pregnancy.

NeuroFlow developed curricula to support both broad population health initiatives as well as Ob-Gyn workflows, in which the pathways are more directly incorporated into patient care. The proven model, which has been developed and refined with other partners across the industry, is attracting the attention of organizations like disability insurers, Medicaid MCOs, and health systems, who are committed to improving the management of maternal populations and recognize the dire need to invest further in their mental health comorbidities. NeuroFlow's ability to measure risk and connect individuals to care pathways, in a variety of at-risk populations, has resulted in a decrease in emergency department utilization and an improved detection of symptoms.

"Our goal is to normalize the challenges of new parenthood and ensure that no parent feels alone or ashamed during this incredibly stressful time," said NeuroFlow Director of Clinical Growth and Strategy Amanda Brooks. "By providing a pathway that augments the care they are receiving from their provider, new and expecting parents' care is improved, and the risk of untreated postpartum mental health conditions is mitigated."

For more information about perinatal and postpartum care support, please visit here.

About NeuroFlow

NeuroFlow helps risk-bearing healthcare organizations improve outcomes and cost of care in medically complex populations by surfacing and supporting behavioral health needs that typically go undetected and under-addressed. Across payors, providers, and the federal government, NeuroFlow's scalable technology and analytics capabilities empower organizations with the behavioral health insights they're missing to manage these populations in a financially sustainable way. Powered by deep expertise in whole-person care, NeuroFlow offers a path to risk predictability and proactive care that helps overcome the systemic challenges in today's healthcare ecosystem.

Media Contact

Sara Cohen, NeuroFlow, 1 610-420-1724, [email protected], neuroflow.com

SOURCE NeuroFlow


These press releases may also interest you

at 20:14
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 19:30
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

at 18:00
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

at 17:20
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...

at 12:20
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...



News published on and distributed by: